Centene's profit recovery accelerates as costs ease and guidance jumps
Q2 earnings blow past estimates, 2026 profit outlook raised sharply Centene reported Q2 adjusted EPS of $2.51, crushing the $1.09 consensus, and raised full-year 2026 profit guidance to over $4.80 from $3.40. The medical loss ratio improved to 89.6% from 93%, showing costs are finally under control. This directly boosts the stock because it signals a faster-than-expected turnaround.
This is the period's biggest new event and the main reason CNC is moving.
Medical cost trend stabilizes, easing two-year industry squeeze Oakmark and other funds noted that the unprecedented spike in medical costs is stabilizing or decelerating. Combined with better pricing and Centene's expense cuts, this points to a multi-year earnings recovery. For investors, it means the worst of the margin pressure may be over, supporting a higher stock price.
Explains the fundamental force behind the profit rebound and why investors are more optimistic.
Trump administration ends Medicare Part D subsidy, raising 2027 premiums The administration is ending a $3.6 billion subsidy that helped insurers keep Part D premiums low. Three out of four enrollees will see higher monthly premiums in 2027, and Centene, as a top Part D insurer, faces reduced government payments and potential membership loss. This is a real counterweight that could pressure future profits.
It is the main negative development this period and a genuine risk to the bullish story.
